Context: There is an increasing population of childhood cancer survivors (CCS) at risk for treatment-related toxicities, including skeletal morbidities. Bone mineral density (BMD) is a proxy for bone health and reductions are associated with osteoporosis and fractures.
Objective: To investigate bone health in CCS by conducting a systematic review and meta-analysis of BMD after completed treatments.
Data sources: We searched Medline, Embase, Cochrane, and Web of Science in May 2019 and updated in May 2023.
Study selection: Studies reporting BMD Z-scores measured with dual-energy x-ray absorptiometry in CCS after treatment completion.
Data extraction: We performed a pooled analysis of studies reporting BMD Z-scores and thereafter we analyzed studies comparing BMD in survivors and healthy controls. All analyses were performed based on the site of BMD measurement.
Results: Of 4243 studies, 84 were included (N = 8106). The mean time off-treatment across the studies ranged from 2 months to 24 years. The overall pooled mean Z-score was -0.57 (95% confidence interval [CI] -0.59 to -0.55) in the whole-body, -0.84 (95% CI -0.86 to -0.83) in the lumbar spine, -0.79 (95% CI -0.81 to -0.77) in the femoral neck and -0.14 (95% CI -0.18 to -0.11) in the total hip. When comparing survivors with controls, BMD was significantly lower in survivors at all sites.
Limitations: English publications, study-level meta-analysis.
Conclusions: We showed a significant reduction of BMD Z-scores in CCS. Given the increased fracture risk already within -1 SD, these results emphasize the need for BMD surveillance and secondary prevention in CCS.
Copyright © 2024 by the American Academy of Pediatrics.